Austco HealthcareASX:AHC +11.36%70 ROE % is 17.20% as of Dec. 2025, which is 47% above its 10-year median of 11.67. GuruFocus rates ASX:AHC with a GF Score™ of 70/100 and a GF Value™ of A$0.33 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Austco Healthcare ranks better than 84.48% on this metric.
The historical rank and industry rank for Austco Healthcare's ROE % or its related term are showing as below:
ASX:AHC'
s ROE % Range Over the Past 10 Years
Min: -62.81 Med: 11.67 Max: 20.4
Current: 14.57
During the past 13 years, Austco Healthcare's highest ROE % was 20.40%. The lowest was -62.81%. And the median was 11.67%.
ASX:AHC's ROE % is ranked better than 84.48% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs ASX:AHC: 14.57
Austco Healthcare (ASX:AHC) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Austco Healthcare ROE % Related Terms
Austco Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Austco Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Austco Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austco Healthcare ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austco Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Austco Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Austco Healthcare (ASX:AHC) has a ROE % of 17.20% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Austco Healthcare and its competitors. This is 47% above median its historical median of 11.67. According to the industry distribution chart, Austco Healthcare ranks #124 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 15.5%.
Is Austco Healthcare's ROE % too high?
Austco Healthcare's current ROE % of 17.20% is 47% above median its 10-year median of 11.67. The Medical Devices & Instruments industry median ROE % is 2.42. Austco Healthcare's value of 17.20% is 610.7% above this industry median. Based on the distribution chart, Austco Healthcare ranks #124 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austco Healthcare has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Austco Healthcare's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Austco Healthcare ranks #124 out of 799 companies for ROE %. This places Austco Healthcare in the top 16% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Austco Healthcare's value of 17.20% is 610.7% above this benchmark. While the company's 10-year median is 11.67 vs. the industry median of 2.42, Austco Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austco Healthcare's current ROE % of 17.20% is 610.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Austco Healthcare and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austco Healthcare's current ROE % is 17.20%, which is 47% above median its own 10-year median of 11.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austco Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Austco Healthcare (ASX:AHC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.33, compared to a current price of A$0.25 — trading 25.8% below its estimated fair value. The current ROE % is 17.20%, which is 47% above median its 10-year median of 11.67 and 610.7% above the Medical Devices & Instruments industry median of 2.42. Austco Healthcare's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Austco Healthcare (ASX:AHC), the current ROE % is 17.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austco Healthcare (ASX:AHC) Overvalued in 2026?
Based on GuruFocus' analysis, Austco Healthcare stock appears to be undervalued.
The current stock price of A$0.25 is trading 25.8% below its estimated GF Value™ of A$0.33.
GuruFocus considers Austco Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:AHC:
ROE %: 17.20% (47% above median its 10-year median of 11.67)
GF Value™: A$0.33 vs. price of A$0.25 (25.8% below fair value)
Industry Position: 610.7% above the Medical Devices & Instruments median (#124 of 799)
No single metric tells the full story. See the ASX:AHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austco Healthcare Ltd engages in the development and provision of electronic communications and clinical management solutions. It offers Tacera, a nurse call, and healthcare communication system for healthcare professionals and patient. The group is segmented into four geographic regions consisting of Australia/New Zealand, Asia, Europe, and North America.
70GF Score
Get the complete analysis for ASX:AHC
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AHC has been successfully added to your 
